Novel approaches to therapy of hypereosinophilic syndromes

Simon, Hans-Uwe; Cools, Jan (2007). Novel approaches to therapy of hypereosinophilic syndromes. Immunology and allergy clinics of North America, 27(3), pp. 519-27. Philadelphia, Pa.: Elsevier 10.1016/j.iac.2007.07.003

Full text not available from this repository. (Request a copy)

There has been recent progress in the understanding of the pathogenesis of the hypereosinophilic syndromes (HES). This led to the distinction of subgroups, in which the underlying cause has been identified. Consequently, new treatment options became available, such as imatinib and mepolizumab, which proved to be promising. This article summarizes these new pharmacologic approaches to the therapy of HES.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Pharmacology

UniBE Contributor:

Simon, Hans-Uwe

ISSN:

0889-8561

ISBN:

17868862

Publisher:

Elsevier

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:54

Last Modified:

04 May 2014 23:15

Publisher DOI:

10.1016/j.iac.2007.07.003

PubMed ID:

17868862

Web of Science ID:

000250174800012

URI:

https://boris.unibe.ch/id/eprint/23008 (FactScience: 38541)

Actions (login required)

Edit item Edit item
Provide Feedback